Navigation Links
OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
Date:10/19/2010

tion of new cancer therapies that address treatment resistance in cancer patients.  OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen, also referred to as OGX-011.  Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer.  The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer in 2011. OGX-427 has entered Phase 2 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.  More information about OncoGenex is available at www.oncogenex.com.

More information about OncoGenex is available at www.oncogenex.com. OncoGenex' Forward Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, OncoGenex' intention to conduct a public offering of common stock and warrants.  All statements other than statements of historical fact are statements that could be deemed forward-looking statements.  These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the ability to manage successfully and complete the public offering, the economic and/or market conditions generally, risks r
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
2. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
3. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
4. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
5. OncoGenex Reports Second Quarter Financial Results
6. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
7. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
8. OncoGenex Reports First Quarter Financial Results
9. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
10. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
11. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... FemCap Inc., www.femcap.com  an innovator in ... a patent No: US, 8,795,248 B2 dated Aug. 5, ... clearance in the U.S., 510(K) K121857, medical device licensure ... is related to its menstrual cup with a unique ... releasing FemmyCycle Teen, a third menstrual cup to complement ...
(Date:9/30/2014)... 2014 SoundConnect, an ... is dedicated to supporting business communication solutions, including ... Power, a carrier services specialist has ... stays connected and productive at all times. This ... of businesses to cloud communications services. On ...
(Date:9/30/2014)... 30, 2014 Back in the 1970’s, many ... feet. per employee, which included space for circulation and file ... Jeff Howell, partner at Nidea Corporate Real Estate / ... “By the year 2000, however, 250 square feet per ... number come down to 175 to 225 square feet, and ...
(Date:9/29/2014)... BEACH, Va. , Sept. 29, 2014 /PRNewswire-USNewswire/ ... from the fields of cartilage repair, regeneration, allograft ... attendees from around the world gathered to discuss ... LifeNet Health Institute of Regenerative Medicine symposium, ... Direction . Topics included Orthopedic Biosurgery, Minced Juvenile ...
Breaking Biology Technology:The FemmyCycle 2SoundConnect Expands Carrier Services Division 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3
... Corp ., a Madison biotechnology company, has raised $1 million ... the total raised to $3 million in the past two ... verify the efficacy of two products: adhesives that bind tissues ... and medical device coatings that block bacterial adhesion to the ...
... - Sir Ken Robinson has many ... his point about creativity than the story of a little ... a senior advisor to the J. Paul Getty Trust ... creativity and innovation, told the story during a keynote address ...
... 1995, I gave a luncheon speech to the Chicago Bar ... st Century." At that time, many who attended ... that much faith in it. My argument was that the ... maxed out. Municipalities would have to become more creative to ...
Cached Biology Technology:Sir Ken Robinson: Companies, kids "get" innovation, but K-12 doesn't nurture it 2Sir Ken Robinson: Companies, kids "get" innovation, but K-12 doesn't nurture it 3Creativity, innovation extend to municipalities 2Creativity, innovation extend to municipalities 3Creativity, innovation extend to municipalities 4
(Date:9/30/2014)... news release is available in German . ... are among the most expensive foods in the world. Because ... find them. But the distinctive smell of truffles is not ... French scientists under the direction of the Goethe University Frankfurt ... produced by soil bacteria which are trapped inside truffle fruiting ...
(Date:9/30/2014)... goes wrong with your muscles because of age, disease or ... is. That,s where a new research report published in the ... comes in. In the report, a team of scientists ... help scientists "see" which genes are active in an organ ... activity and that men have approximately 400 more active genes ...
(Date:9/30/2014)... suite of perilous threats in today,s ocean. From ... change, fragile coral ecosystems are disappearing at unprecedented ... species of corals surrounding the island of Moorea ... their tropical environment: coral guard-crabs. New research from ... Station scientist Seabird McKeon and the museum,s predoctoral ...
Breaking Biology News(10 mins):On the trail of the truffle flavor 2Scientists identify which genes are active in muscles of men and women 2Smithsonian scientists discover coral's best defender against an army of sea stars 2
... United States are changing and will face reduced growth ... this century, according to a study conducted by a ... of California, Santa Barbara; U.S. Geological Survey; and University ... Proceedings of the National Academy of Sciences ...
... It,s colds and flu season, and as any parent knows, ... New research using human-networking theory may give a clearer picture ... cold, influenza, whooping cough and SARS can spread through a ... With the help of 788 volunteers at a high ...
... ever, scientists have found a difference in the way males and ... that sexes likely use that difference to select their mates. ... team of researchers who found that male and female cichlid fishes ... as well. "It is difficult to say what colour ...
Cached Biology News:Drought and rising temperatures weaken southwest forests 2Human networking theory gives picture of infectious disease spread 2Human networking theory gives picture of infectious disease spread 3When it comes to selecting a mate, the eyes have it: Queen's University study 2